Scarica l'app Stockscreener
30.16
1.02%
-0.60
Precedente Chiudi:
$30.76
Aprire:
$30.81
Volume 24 ore:
154.70K
Relative Volume:
0.15
Capitalizzazione di mercato:
$2.45B
Reddito:
$399.58M
Utile/perdita netta:
$-54.04M
Rapporto P/E:
-40.21
EPS:
-0.75
Flusso di cassa netto:
$40.13M
1 W Prestazione:
-0.38%
1M Prestazione:
-4.26%
6M Prestazione:
-22.98%
1 anno Prestazione:
+35.31%
Intervallo 1D:
$30.16
$30.99
Intervallo di 1 settimana:
$27.24
$32.35
Portata 52W:
$19.73
$47.32
Veracyte Inc Stock (VCYT) Company Profile
Nome
Veracyte Inc
Settore
Industria
Telefono
(650) 243-6300
Indirizzo
6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO, CA
Confronta VCYT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VCYT
Veracyte Inc
|
30.16 | 2.45B | 399.58M | -54.04M | 40.13M | -0.75 |
|
TMO
Thermo Fisher Scientific Inc
|
432.33 | 159.40B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
198.78 | 136.01B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
506.13 | 38.21B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
115.84 | 30.90B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IQV
Iqvia Holdings Inc
|
153.09 | 26.35B | 15.50B | 1.33B | 2.16B | 7.34 |
Veracyte Inc Stock (VCYT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-20 | Iniziato | Craig Hallum | Buy |
| 2024-12-05 | Downgrade | Goldman | Buy → Neutral |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-10-16 | Iniziato | UBS | Buy |
| 2024-10-10 | Iniziato | Guggenheim | Buy |
| 2024-02-23 | Reiterato | Needham | Buy |
| 2023-01-18 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2023-01-05 | Iniziato | Scotiabank | Sector Outperform |
| 2022-01-07 | Iniziato | Stephens | Overweight |
| 2021-11-18 | Ripresa | Goldman | Buy |
| 2021-06-15 | Iniziato | Raymond James | Outperform |
| 2021-02-18 | Ripresa | Needham | Buy |
| 2021-01-28 | Iniziato | Truist | Buy |
| 2020-11-10 | Iniziato | KeyBanc Capital Markets | Sector Weight |
| 2020-09-09 | Iniziato | Morgan Stanley | Underweight |
| 2019-07-31 | Iniziato | Lake Street | Buy |
| 2019-07-02 | Iniziato | Needham | Buy |
| 2018-11-29 | Downgrade | Janney | Buy → Neutral |
| 2018-10-31 | Aggiornamento | Janney | Neutral → Buy |
| 2017-11-07 | Downgrade | Janney | Buy → Neutral |
| 2017-11-07 | Downgrade | Piper Jaffray | Overweight → Neutral |
| 2017-08-31 | Ripresa | BTIG Research | Buy |
| 2016-11-14 | Ripresa | Leerink Partners | Outperform |
| 2015-12-18 | Iniziato | Cantor Fitzgerald | Buy |
| 2015-06-11 | Reiterato | Leerink Partners | Outperform |
| 2013-11-26 | Iniziato | William Blair | Outperform |
Mostra tutto
Veracyte Inc Borsa (VCYT) Ultime notizie
Veracyte projects strong Decipher and Afirma growth, targets 22.5% adjusted EBITDA margin for 2025 - MSN
Veracyte, Inc. Just Beat EPS By 260%: Here's What Analysts Think Will Happen Next - simplywall.st
Veracyte, Inc. Just Recorded A 260% EPS Beat: Here's What Analysts Are Forecasting Next - Yahoo Finance
Veracyte Stock Gains on Q1 Earnings and Revenue Beat, Gross Margin Up - Zacks Investment Research
Veracyte First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Decoding Veracyte Inc (VCYT): A Strategic SWOT Insight - GuruFocus
Veracyte Inc earnings beat by $0.29, revenue topped estimates - Investing.com Nigeria
Veracyte (VCYT) Target Price Lowered by UBS | VCYT Stock News - GuruFocus
What Makes Veracyte (VCYT) a New Buy Stock - Yahoo Finance
Veracyte shares target cut to $41 by Needham, keeps buy rating - Investing.com Nigeria
Veracyte, Inc. (NASDAQ:VCYT) Q1 2025 Earnings Call Transcript - Insider Monkey
UBS Adjusts Price Target for Veracyte (VCYT) Amid Growth Potential | VCYT Stock News - GuruFocus
UBS Cuts Price Target on Veracyte to $42 From $49, Keeps Buy Rating - marketscreener.com
VERACYTE, INC. SEC 10-Q Report - TradingView
Breaking Down Veracyte: 7 Analysts Share Their Views - Benzinga
Veracyte (VCYT) Target Price Lowered by Needham Analyst | VCYT Stock News - GuruFocus
Veracyte: Q1 Earnings Snapshot - Norwalk Hour
Veracyte Inc (VCYT) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Expansions - Yahoo Finance
Veracyte Reports Strong Q1 2025 Financial Growth - TipRanks
Veracyte (VCYT) Reports Strong Q1 Growth Driven by Decipher and Afirma - GuruFocus
Veracyte Announces First Quarter 2025 Financial Results - BioSpace
Veracyte Q1 2025 Earnings Call Transcript - MarketBeat
Earnings call transcript: Veracyte Q1 2025 sees strong revenue growth, stock surges - Investing.com Australia
Veracyte Inc (VCYT) Q1 2025 Earnings: EPS of $0.09 Beats Estimat - GuruFocus
Veracyte (VCYT) Q1 Earnings and Revenues Beat Estimates - Yahoo Finance
Veracyte Q1 2025 slides: 18% revenue growth, transition to profitability By Investing.com - Investing.com South Africa
Veracyte Q1 2025 slides: 18% revenue growth, transition to profitability - Investing.com
Veracyte (VCYT) Exceeds Q1 Revenue Projections with Strong Testi - GuruFocus
Veracyte (VCYT) Reaffirms 2025 Revenue Outlook Amid Strong Performance | VCYT Stock News - GuruFocus
Veracyte Inc (VCYT) Q1 2025 Earnings: EPS of $0.09 Beats Estimates, Revenue Surges to $114.5 Million - GuruFocus
Earnings Flash (VCYT) VERACYTE INC. Reports Q1 Revenue $114.5M, vs. FactSet Est of $111.3M - marketscreener.com
Breaking Down the Benefits of Clinical Trial Participation in Cancer Care - Curetoday
Veracyte Announces Expanded Availability of Decipher Prostate Test to Patients with Metastatic Prostate Cancer - BioSpace
Veracyte launches prostate metastatic test - MSN
Crafting an Individual Treatment Plan for Patients With Prostate Cancer - Curetoday
Cathie Wood's Ark Invest Loads Up On Intellia Therapeutics, Offloads Meta Platforms - Benzinga
Veracyte launches metastatic prostate cancer test - Investing.com
Veracyte launches metastatic prostate cancer test By Investing.com - Investing.com South Africa
Veracyte launches prostate metastatic test (VCYT:NASDAQ) - Seeking Alpha
Veracyte (VCYT) Boosts Cancer Care with New Genomic Classifier Launch | VCYT Stock News - GuruFocus
Veracyte Announces Expanded Availability of Decipher Prostate Te - GuruFocus
Veracyte (VCYT) Boosts Cancer Care with New Genomic Classifier L - GuruFocus
Veracyte Announces Expanded Availability Of Decipher Prostate Test To Patients With Metastatic Prostate Cancer - marketscreener.com
Veracyte Announces Expanded Availability of Decipher Prostate Test to Patients with Metastatic Prostate Cancer | VCYT Stock News - GuruFocus
Press Release Distribution & PR Platform - ACCESS Newswire
Veracyte Announces Multiple Abstracts Demonstrating Power of Dec - GuruFocus
Veracyte Inc Azioni (VCYT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.94%
2.86%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):